Romosozumab increases bone mineral density post-menopause

Romosozumab increases bone mineral density post-menopause
Romosozumab seems safe and effective for increasing bone mineral density in postmenopausal women with low bone mineral density, according to a study published online Jan. 1 in the New England Journal of Medicine.

(HealthDay)—Romosozumab seems safe and effective for increasing bone mineral density in postmenopausal women with low bone mineral density, according to a study published online Jan. 1 in the New England Journal of Medicine.

Michael R. McClung, M.D., from the Oregon Osteoporosis Center in Portland, and colleagues conducted a phase 2 study to examine the efficacy and safety of romosozumab over a 12-month period in 419 , aged 55 to 85 years of age, with low density. Participants were randomized to receive subcutaneous romosozumab every month (70, 140, or 210 mg) or every three months (140 or 210 mg), placebo, or an active comparator (70 mg weekly alendronate or 20 µg daily teriparatide).

The authors identified significant increases in bone mineral density at the lumbar spine with all dose levels of romosozumab, including a 11.3 percent increase with the 210-mg monthly dose, compared with a 0.1 percent decrease with placebo and 4.1 and 7.1 percent increases with alendronate and teriparatide, respectively. Large increases in bone mineral density were seen at the total hip and femoral neck, as well as transitory increases in markers with romosozumab, while sustained decreases were observed in a marker. Adverse events were similar between the groups, except for mild, generally nonrecurring injection-site reactions with romosozumab.

"Romosozumab was associated with increased and bone formation and with decreased bone resorption," the authors write.

Several authors disclosed financial ties to pharmaceutical companies, including Amgen and UCB Pharma, which funded the study.

More information: Abstract
Full Text
Editorial

add to favorites email to friend print save as pdf

Related Stories

Alendronate reduces adjacent-level vertebral fractures

Dec 30, 2013

(HealthDay)—For females with osteoporosis, the rate of adjacent-level vertebral fractures is relatively low, with reduced odds with bisphosphonate therapy, according to a study published in the Dec. 1 issue ...

Recommended for you

Senegal monitors contacts of 1st Ebola patient

1 hour ago

Senegalese authorities on Monday were monitoring everyone who was in contact with a student infected with Ebola who crossed into the country, and who has lost three family members to the disease.

Cerebral palsy may be hereditary

7 hours ago

Cerebral palsy is a neurological developmental disorder which follows an injury to the immature brain before, during or after birth. The resulting condition affects the child's ability to move and in some ...

19 new dengue cases in Japan, linked to Tokyo park

13 hours ago

Japan is urging local authorities to be on the lookout for further outbreaks of dengue fever, after confirming another 19 cases that were contracted at a popular local park in downtown Tokyo.

User comments